Literature DB >> 1714887

Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial.

S A Taylor1, J Crowley, F S Vogel, J J Townsend, H J Eyre, K A Jaeckle, H E Hynes, J T Guy.   

Abstract

Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1714887     DOI： 10.1007/bf00175089

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  2 in total

1.  Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study.

Authors:  D R Spriggs; E Stopa; R J Mayer; W Schoene; D W Kufe
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

2.  Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.

Authors:  J J Hutton; D D Von Hoff; J Kuhn; J Phillips; M Hersh; G Clark
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701
  2 in total
  4 in total

Review 1.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 2.  New agents in the treatment of primary brain tumors.

Authors:  S A Taylor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 3.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 4.  Marine Natural Products in Clinical Use.

Authors:  Neshatul Haque; Sana Parveen; Tingting Tang; Jiaen Wei; Zunnan Huang
Journal:  Mar Drugs       Date:  2022-08-18       Impact factor: 6.085
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.